This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Feher, M. D Articles by Elkeles, R. S Search for Related Content Social Bookmarking                         What's this?

Fenofibrate in type 2 diabetes: The FIELD study

Fibrate Intervention and Event Lowering in Diabetes (FIELD)

Beta Cell Diabetes Centre, Chelsea & Westminster Hospital, London SW10 9NH, UK, michael.feher{at}chelwest.nhs.uk

Robert S Elkeles

Unit for Metabolic Medicine, St Marys Hospital, London, W2 1NY, UK

Key Words: fenofibrate • type 2 diabetes.

References

• The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Feher MD, Caslake M., Foxton J., Cox A., Packard CJ Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999;15:395-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Diabetes Atherosclerosis Intervention Study Investigators. Effects of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Madej A., Okopien B., Kowalski J. et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinaemia IIB. Int J Clin Pharmacol Ther 1998;36:345-9.[Web of Science][Medline] [Order article via Infotrieve]
• Keating GM, Ormrod D.: Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002, 62:1909-44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Turner RC, Millns H., Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823-8.[Abstract/Free Full Text]
• Colhoun HM, Betteridge DJ, Durrington PN et al. (Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V. Fuller JH,) on behalf of the CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Collins R., Armitage J., Parish S. et al. for the Heart Protection Study Collaborative Group. MRC/BHF heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rubins HB, Robins SJ, Collins D. et al. (Fye CL, Anderson JW, Elam BM, Faas FH, Linares E., Schaefer EJ, Schectman G., Wilt TJ, Wittes J.): Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density lipoprotein cholesterol Intervention Trial study group. N Engl J Med 1999;341:410-18.[Abstract/Free Full Text]
• Davidson MH Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002;90:50K-60K.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Elkeles RS, Diamond JR, Poulter C. et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998;21:641-8.[Abstract]
• Frick MH, Elo O., Haapa K. et al. (Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V and others): Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety treatment, changes in risk factors and incidence of coronary heart disease. N Eng J Med 1987;317:1237-45.
• Koskinen P., Mänttäri M., Manninen V., Huttunen JK, Heinonen OP, Frick MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.[Abstract]
• ACCORD - trial information for recruitment www.clinicaltrials.gov/ct/show/NCT00000620

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 6, 330-333 (2005)
DOI: 10.1177/14746514050050060601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. J Krentz Effective management of type 2 diabetes and metabolic syndrome: beyond glucose control The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 303 - 304. [PDF]

				S. H Wild and C. D Byrne Review: Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 315 - 319. [Abstract] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Feher, M. D Articles by Elkeles, R. S Search for Related Content Social Bookmarking                         What's this?